Cargando…

Ribociclib Plus Letrozole in Italian Male Patients with Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Case Studies of Phase 3b CompLEEment-1 Trial

ABSTRACT: Male breast cancer (BC) is rare, globally constituting only 0.5–1% of all patients with BC. In Italy, more than 2000 new male BC cases were registered between 2000 and 2014. The survival rate was lower in males than in females. Delayed diagnosis may be the reason for poorer outcome observe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Caputo, Roberta, Fabi, Alessandra, Romagnoli, Emanuela, Baldini, Editta, Grasso, Donatella, Fenderico, Nicola, Michelotti, Andrea
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2022
Materias:	Case Series
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9576937/ https://www.ncbi.nlm.nih.gov/pubmed/36267663 http://dx.doi.org/10.2147/BCTT.S376902

Ejemplares similares

Safety and Efficacy of Ribociclib in Combination with Letrozole in Patients with HR+, HER2− Advanced Breast Cancer: Results from the Italian Subpopulation of Phase 3b CompLEEment-1 Study
por: De Laurentiis, Michelino, et al.
Publicado: (2022)

Ribociclib plus letrozole in subgroups of special clinical interest with hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer: Subgroup analysis of the phase IIIb CompLEEment-1 trial
por: Cottu, Paul, et al.
Publicado: (2022)

Safety and efficacy of ribociclib plus letrozole in patients with HR+, HER2– advanced breast cancer: Results from the Spanish sub-population of the phase 3b CompLEEment-1 trial
por: Salvador Bofill, Javier, et al.
Publicado: (2022)

Ribociclib Plus Letrozole in Patients with Hormone Receptor-positive, HER2-negative Advanced Breast Cancer with No Prior Endocrine Therapy: Subgroup Safety Analysis from The Phase 3b CompLEEment-1 Trial
por: Borstnar, Simona, et al.
Publicado: (2022)

Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population
por: De Laurentiis, Michelino, et al.
Publicado: (2021)

Correction to: Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population
por: De Laurentiis, Michelino, et al.
Publicado: (2021)

Cost-effectiveness analysis of ribociclib plus letrozole versus palbociclib plus letrozole in the United Kingdom
por: Suri, Gaurav, et al.
Publicado: (2019)

Phase II trial of ribociclib and letrozole in patients with relapsed oestrogen receptor-positive ovarian or endometrial cancers
por: Colon-Otero, Gerardo, et al.
Publicado: (2020)

Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial
por: Sonke, Gabe S., et al.
Publicado: (2017)

Health-related quality of life of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with ribociclib + letrozole: results from MONALEESA-2
por: Verma, Sunil, et al.
Publicado: (2018)

Cost-utility analysis of Palbociclib + letrozole and ribociclib + letrozole versus Letrozole monotherapy in the first-line treatment of metastatic breast cancer in Iran using partitioned survival model
por: Darvishi, Ali, et al.
Publicado: (2023)

Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2− advanced breast cancer in the randomized MONALEESA-2 trial
por: O’Shaughnessy, Joyce, et al.
Publicado: (2017)

Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer
por: Hortobagyi, G N, et al.
Publicado: (2019)

Thromboembolic Events in Patients with HER2-Negative, Hormone Receptor-Positive, Metastatic Breast Cancer Treated with Ribociclib Combined with Letrozole or Fulvestrant: A Real-World Data
por: Abdel-Razeq, Hikmat, et al.
Publicado: (2022)

Comparative efficacy & safety of buparlisib plus fulvestrant, fulvestrant plus dalpiciclib, and ribociclib plus letrozole for postmenopausal, hormone receptor-positive, and HER2-negative breast cancer
por: Liu, Qi, et al.
Publicado: (2023)

Cost-Effectiveness of Ribociclib plus Letrozole Versus Palbociclib plus Letrozole and Letrozole Monotherapy in the First-Line Treatment of Postmenopausal Women with HR+/HER2- Advanced or Metastatic Breast Cancer: A U.S. Payer Perspective
por: Mistry, Rohit, et al.
Publicado: (2018)

Simultaneous quantification of palbociclib, ribociclib and letrozole in human plasma by a new LC-MS/MS method for clinical application
por: Posocco, Bianca, et al.
Publicado: (2020)

Cost-effectiveness of ribociclib plus letrozole versus palbociclib plus letrozole or letrozole as monotherapy in first-line treatment of postmenopausal women with HR+/HER2− locally advanced or metastatic breast cancer: a Brazilian private payer perspective
por: Buehler, Anna Maria, et al.
Publicado: (2021)

Comprehensive Genomic Profiling of Cell-Free Circulating Tumor DNA Detects Response to Ribociclib Plus Letrozole in a Patient with Metastatic Breast Cancer
por: Silveira, Catarina, et al.
Publicado: (2022)

Palbociclib plus letrozole as treatment for postmenopausal women with hormone receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer for whom letrozole therapy is deemed appropriate: An expanded access study in Australia and India
por: Loi, Sherene, et al.
Publicado: (2021)

Matching-Adjusted Indirect Comparison of Ribociclib Plus Fulvestrant versus Palbociclib Plus Letrozole as First-Line Treatment of HR+/HER2− Advanced Breast Cancer
por: Fasching, Peter A, et al.
Publicado: (2021)

Cost-Effectiveness of Ribociclib for Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer
por: Yang, Jiangping, et al.
Publicado: (2020)

Ribociclib Induced Photosensitive Skin Lesions
por: Verma, Vaishnavi, et al.
Publicado: (2022)

Combination of Ribociclib and Gemcitabine for the Treatment of Medulloblastoma
por: Pribnow, Allison, et al.
Publicado: (2022)

Ribociclib and Abemaciclib: CDK4/6 Inhibitors for the Treatment of Hormone Receptor–Positive Metastatic Breast Cancer
por: Byers, Kristina F.
Publicado: (2021)

Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up
por: Rugo, H. S., et al.
Publicado: (2019)

Palbociclib in combination with letrozole in patients with estrogen receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer: PALOMA-2 subgroup analysis of Japanese patients
por: Mukai, Hirofumi, et al.
Publicado: (2018)

Exploring treatment with Ribociclib alone or in sequence/combination with Everolimus in ER(+)HER2(−)Rb wild-type and knock-down in breast cancer cell lines
por: Marinelli, Oliviero, et al.
Publicado: (2020)

Ribociclib-induced Vitiligo: a Case Report
por: Silvestre Torner, Nicolás, et al.
Publicado: (2022)

Pyrotinib in combination with letrozole for hormone receptor-positive, human epidermal growth factor receptor 2-positive metastatic breast cancer (PLEHERM): a multicenter, single-arm, phase II trial
por: Hu, Zhe-Yu, et al.
Publicado: (2023)

Development and Validation of a Novel LC-MS/MS Method for the Simultaneous Determination of Abemaciclib, Palbociclib, Ribociclib, Anastrozole, Letrozole, and Fulvestrant in Plasma Samples: A Prerequisite for Personalized Breast Cancer Treatment
por: Turković, Lu, et al.
Publicado: (2022)

Efficacy and safety of palbociclib and ribociclib in patients with estrogen and/or progesterone receptor positive, HER2 receptor negative metastatic breast cancer in routine clinical practice
por: Rath, Sushmita, et al.
Publicado: (2021)

Proliferation, steroid receptors and clinical/pathological response in breast cancer treated with letrozole
por: Miller, W R, et al.
Publicado: (2006)

Combination of androgen receptor inhibitor enzalutamide with the CDK4/6 inhibitor ribociclib in triple negative breast cancer cells
por: Choupani, Edris, et al.
Publicado: (2022)

Real World Experience of Second-Line Treatment Strategies after Palbociclib and Letrozole: Overall Survival in Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer
por: Kim, Ji-Yeon, et al.
Publicado: (2023)

Phase II randomized trial of neoadjuvant metformin plus letrozole versus placebo plus letrozole for estrogen receptor positive postmenopausal breast cancer (METEOR)
por: Kim, Jisun, et al.
Publicado: (2014)

Case Report of Probable DRESS Syndrome Associated with Ribociclib
por: Carneiro, Florian, et al.
Publicado: (2023)

A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degrader, with or without Ribociclib or Alpelisib, in Patients with Estrogen Receptor–Positive Breast Cancer
por: Jhaveri, Komal, et al.
Publicado: (2021)

Use of programmed cell death protein ligand 1 assay to predict the outcomes of non-small cell lung cancer patients treated with immune checkpoint inhibitors
por: Tibaldi, Carmelo, et al.
Publicado: (2017)

A comparison of letrozole and anastrozole followed by letrozole in breast cancer patients
por: Aphinives, Potchavit, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_s93figeepkmu0cumpls08me5nd